Compulsory licensing: explore five articles on The Compulsory-Licensing Clock Depends on the Statutory Ground, Government Use Does Not Always Require a National Emergency, Authorised Use Requires Remuneration, Not an Infringement Penalty. Use the contents below to jump to a topic, and follow the related guides to continue your reading.
Adapted from a manuscript by Lawrence Yip.
General information, not legal advice. These articles reflect the supplied editorial collection and its citation audit; check current law and the original authorities before relying on them.
The Compulsory-Licensing Clock Depends on the Statutory Ground
Not every Malaysian compulsory-licensing ground operates under the same timetable. Section 49(1) addresses specified failures of production or adequate domestic supply, without a legitimate reason, after the later of three years from grant and four years from filing.[54]
That waiting period should not be described as governing every application under section 49. The additional grounds in subsection (1A) are available at any time after grant, subject to their own conditions. Identifying the legal ground must therefore precede calculating the earliest application date.
The production and supply language also requires precision. An application should address the Malaysian circumstances specified by the provision and the patent owner’s explanation for the alleged shortfall. General dissatisfaction with availability is not a substitute for establishing the statutory facts.
For the proposed beneficiary, evidence of demand and inadequate supply should be linked to a workable plan for exploiting the invention. Obtaining permission is of little practical value if the beneficiary cannot provide the supply relied upon to justify it.
The lesson is to begin with the ground, not the form. A defensible application combines the correct timetable, evidence addressing the relevant statutory conditions and a realistic explanation of how the proposed authorisation will remedy the identified problem.
Sources and case references
- Patents Act 1983 (Act 291) (Malaysia), section 49(1), (1A).
Government Use Does Not Always Require a National Emergency
Section 84 provides alternatives rather than a universal emergency requirement. It permits government use where a national emergency exists or where the specified public interest requires exploitation, and separately addresses determined anti-competitive exploitation.[55]
A public-health programme may therefore require analysis under the public-interest ground without treating a formal emergency as indispensable. That does not mean socially desirable use is automatically authorised. The competent Minister must exercise the statutory power, and the resulting permission must be confined to its authorised purpose and conditions.
The institutional distinction also matters. Compulsory licensing under Part X involves the Registrar’s application-based framework. Government use involves the Minister responsible for intellectual property and a Government agency or designated third person. A procurement decision and the patent authorisation perform different functions.
The practical record should explain the need, the relevant patents, the beneficiary and the acts to be authorised. Public statements about a programme do not replace a clear account of the legal permission governing its implementation.
The lesson is to distinguish absence of an emergency requirement from absence of legal safeguards. Government use can respond to a defined public need while preserving notice, remuneration, limits on exploitation and the statutory opportunity to challenge the decision.
Sources and case references
- Patents Act 1983 (Act 291) (Malaysia), sections 3 (Minister) and 84(1)–(4), (12).
Authorised Use Requires Remuneration, Not an Infringement Penalty
Remuneration under a compulsory licence or government-use authorisation is part of lawful permission. It should not be confused with damages for unauthorised infringement. Sections 52 and 84 provide the relevant Malaysian framework, with government-use remuneration taking account of the economic value of the authorisation.[56]
The statute does not prescribe a universal royalty percentage for every invention or public programme. The permission being valued matters: its duration, authorised activities and restrictions may differ significantly from an unrestricted commercial licence.
The calculation also needs a clear base. A percentage of which receipts, or an amount for which units, must be specified before the resulting payment can be understood. Reporting, payment periods and verification arrangements can be as important in practice as agreement on the headline rate.
For the patent owner, the assessment should identify the protected contribution and the value of the permission actually granted. For the beneficiary, the terms should permit predictable compliance without obscuring the owner’s statutory entitlement.
The practical lesson is to draft remuneration as an operative payment arrangement. A rate unsupported by a defined base and reporting mechanism invites disagreement. Treating it as compensation for a wrong is equally misleading where the relevant exploitation falls within a valid statutory authorisation.
Sources and case references
- Patents Act 1983 (Act 291) (Malaysia), sections 52(c) and 84(3); Agreement on Trade-Related Aspects of Intellectual Property Rights (1994), Article 31(h).
Cross-Border Medicine Supply Requires More Than One Patent Permission
A Malaysian authorisation cannot, by itself, remove a patent obstacle in an exporting country. Pharmaceutical supply under the compulsory-licensing framework therefore requires the legal position at both ends of the transaction to be examined.[57]
Section 49(1A)(b) provides a Malaysian production-and-export route for an eligible importing country’s public-health needs. Its conditions should not be reduced to general permission to export medicines anywhere. Product, destination and authorised supply must fit the statutory and international framework.
For importation under government use, section 84(5A) addresses remuneration where adequate remuneration is paid to the patent owner in the exporting country. The condition matters. It does not make every imported medicine royalty-free merely because a Malaysian public programme purchases it.
The practical inquiry first identifies whether patent permission is needed in the supplying jurisdiction. Where no relevant foreign patent prevents lawful manufacture and export, an export compulsory licence may be unnecessary. Where a relevant right does create an obstacle, Malaysian permission does not resolve it automatically.
The lesson is to map the complete supply chain. Manufacturing, export, importation and domestic distribution may engage different territorial rights. A legally sound public-health arrangement must connect the relevant permissions rather than assume that one authorisation travels with the product across every border.
Sources and case references
- Patents Act 1983 (Act 291) (Malaysia), sections 49(1A)(b) and 84(5A); Agreement on Trade-Related Aspects of Intellectual Property Rights (1994), Article 31bis and Annex.
Sofosbuvir Government Use Was an Authorisation, Not a Judicial Precedent
Malaysia’s 2017 sofosbuvir measure illustrates government use in practice, but it was not a judgment invalidating a patent. The Minister of Health’s statement of 20 September 2017 announced the approved exercise of government rights to improve access to hepatitis C treatment through specified government facilities.[58]
The distinction limits what the episode establishes. An administrative authorisation may permit particular activities while the patent remains legally in existence. It does not mean that every trader is free to import and sell the medicine without regard to the authorisation’s beneficiaries, purpose or conditions.
Nor does the episode supply a judicial ratio decidendi on every question of remuneration or public non-commercial use. Its value is as an example of how the statutory mechanism can support a defined treatment programme.
Patent permission and implementation should also remain separate. Product registration, procurement, distribution and clinical arrangements are not completed merely by removing a patent obstacle. Records of actual supply and treatment are needed to evaluate what the programme achieved.
The practical lesson is to describe the measure accurately: a defined exercise of government rights within the patent system. Its policy significance is substantial without converting an administrative decision into a universal exemption or a reported court ruling.
Sources and case references
- Minister of Health Malaysia, “Implementation of the Rights of Government for Sofosbuvir Tablet to Increase Access for Hepatitis C Treatment in Malaysia” (press statement, 20 September 2017), paragraphs 2–4.

